- Home
- GRC vs MLYS Comparison
GRC vs MLYS Comparison
Compare GRC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRC
- MLYS
- Stock Information
- Founded
- GRC 1933
- MLYS 2019
- Country
- GRC United States
- MLYS United States
- Employees
- GRC N/A
- MLYS N/A
- Industry
- GRC Fluid Controls
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- GRC Industrials
- MLYS Health Care
- Exchange
- GRC Nasdaq
- MLYS Nasdaq
- Market Cap
- GRC 942.4M
- MLYS 893.0M
- IPO Year
- GRC N/A
- MLYS 2023
- Fundamental
- Price
- GRC $32.39
- MLYS $12.24
- Analyst Decision
- GRC
- MLYS Strong Buy
- Analyst Count
- GRC 0
- MLYS 3
- Target Price
- GRC N/A
- MLYS $33.00
- AVG Volume (30 Days)
- GRC 77.2K
- MLYS 2.3M
- Earning Date
- GRC 04-24-2025
- MLYS 05-08-2025
- Dividend Yield
- GRC 2.19%
- MLYS N/A
- EPS Growth
- GRC 14.58
- MLYS N/A
- EPS
- GRC 1.53
- MLYS N/A
- Revenue
- GRC $659,667,000.00
- MLYS N/A
- Revenue This Year
- GRC $4.76
- MLYS N/A
- Revenue Next Year
- GRC $4.50
- MLYS N/A
- P/E Ratio
- GRC $22.12
- MLYS N/A
- Revenue Growth
- GRC 0.02
- MLYS N/A
- 52 Week Low
- GRC $30.47
- MLYS $8.24
- 52 Week High
- GRC $43.79
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- GRC 28.50
- MLYS 46.14
- Support Level
- GRC $34.69
- MLYS $13.00
- Resistance Level
- GRC $36.32
- MLYS $17.17
- Average True Range (ATR)
- GRC 1.02
- MLYS 1.44
- MACD
- GRC -0.30
- MLYS -0.46
- Stochastic Oscillator
- GRC 19.76
- MLYS 2.19
About GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.